Senior researcher/cancer epidemiologist for IKNL #epitwitter
Nijmegen
Joined March 2009
- Tweets1.2K
- Following233
- Followers138
- Likes2.9K
Pinned Tweet
📣 New paper online! 📣
With a team from @IKNL @radboudumc and @QueensKingston we assessed primary end point changes in #Immunotherapy trials. We advocate for more transparency.
#ASCO23 #ASCO2023 #oncology
Changes to primary endpoints during or even after recruitment were omnipresent in phase-III trials with checkpoint inhibitors for urological and lung cancer patients. These changes were often not reported, as stipulated by CONSORT reporting guidelines. ja.ma/3qv10SK
Anke Richters retweeted
⚡️ Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice
#BladderCancer @NatRevClinOncol
nature.com/articles/s41571-0…
Anke Richters retweeted
🚨 #Vapes van kinderen in lab onderzocht: vol gif, lood en te veel #nicotine. «Als je bedenkt dat dit wordt gebruikt door kinderen met nog niet ontwikkelde hersenen, is hier echt sprake van een schadelijk product.» Ik trek al langer aan die alarmbel ... rtl.nl/nieuws/artikel/545056…
Anke Richters retweeted
A new study shows that primary endpoints are often changed after the fact in randomized trials of immunotherapy. In some cases, these changes led to substantially altered conclusions.
Changes to primary endpoints during or even after recruitment were omnipresent in phase-III trials with checkpoint inhibitors for urological and lung cancer patients. These changes were often not reported, as stipulated by CONSORT reporting guidelines. ja.ma/3P1dxHk
Anke Richters retweeted
Changes to primary endpoints during or even after recruitment were omnipresent in phase-III trials with checkpoint inhibitors for urological and lung cancer patients. These changes were often not reported, as stipulated by CONSORT reporting guidelines. ja.ma/3P1dxHk
Anke Richters retweeted
Tientallen liters kankerverwekkend benzeen lopen zo de Maas in. Medewerkers staan in giftige dampen, raken onwel en gewond. En instanties? Die weten er al 3jr van maar grijpen nauwelijks in nrc.nl/nieuws/2023/07/26/lit…
Anke Richters retweeted
In a new Review now live online, Lambertus Kiemeney at co-authors discuss 'Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice' nature.com/articles/s41571-0… #blcsm #hsronc #caepid
Anke Richters retweeted
Goede vraag.
@volkskrant
volkskrant.nl/cs-b2f979c3
Anke Richters retweeted
No matter what you were taught,
don't bother to test for proportional hazards
in survival analyses.
Hazards are never proportional because hazard ratios vary over the follow-up if treatment has an effect on survival.
@mats_julius and I explain it here:
jamanetwork.com/journals/jam…
Anke Richters retweeted
Ontluisterend fragment. CEO @albertheijn Van Egmond zet zichzelf ongenadig te kijk met dit moreel vacueus gemompel. En bevestigt expliciet dat alleen strikte tabaksregulering door overheid helpt om bedrijfsleven in beweging te krijgen. #tabaknee
Albert Heijn verkoopt in tegenstelling tot een concurrent nog wel sigaretten. 'Het gaat erom hoe je mensen het beste helpt’, zegt CEO Marit van Egmond in Geld of je Leven. 'Als je het niet meer aanbiedt, zeg je eigenlijk: je bent niet meer welkom bij ons.' bit.ly/3gehHfZ
Clinical trial Q for #StatsTwitter #MedTwitter #EpiTwitter:
Can you assume exchangeability between arms within strata of a patient-level factor if randomization was not stratified for this factor?
And if it’s stratified for other factors associated with this subgroup factor?
Anke Richters retweeted
National Geographic Picture of The Year. Black images are shadows of zebras. Zoom in and you will see zebras.
Anke Richters retweeted
It is currently believed that cisplatin provides greater benefits than carboplatin; this requires re-evaluation. Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial ... sciencedirect.com/science/ar…
Anke Richters retweeted
On #WorldCancerDay we jointly call on MEPs to adopt the @EP_BeatCancer report at the next plenary, with no weakening of its recommendations on #prevention. It has the right level of ambition to address key risk factors of cancer & other #NCDs bit.ly/3L9H6T5 #EUCancerPlan
Anke Richters retweeted
A nice reminder that HR is not a RELATIVE RISK
(or at least as commonly understood!)
ncbi.nlm.nih.gov/pmc/article…
#epitwitter #gerionc #oncology
8/9
A non-randomized comparison of cisplatin and carboplatin regimens was recently performed in a Dutch cohort of contemporary mUC patients, confirming this finding as well. #bladdercancer
xitter.cf/EurUrolFocus/status/14…
Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study - buff.ly/3uHIFQr
9/9
At the same time, higher tox levels & lower eligibility for cisplatin are well-established. In light of these data, we think revision of guideline language on this topic is necessary.
Read the full OA paper here:
sciencedirect.com/science/ar…
@uroweb @MariaJRibal @myesmo #EAU